ORAMED PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
ORMP$4.00+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of changes in equity
**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
in thousands
Attributable to Company’s Stockholders
| Additional · Total · Non- | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · paid-in · Accumulated · stockholders’ · controlling · Total | |||||||
| Shares | $ | capital | deficit | equity | interests | Equity | |
| In thousands | |||||||
| BALANCE AS OF JANUARY 1, 2023 | 39,564 | 476 | 314,417 | (163,081) | 151,812 | (656) | 151,156 |
| SHARES ISSUED FOR SERVICES | 3 | * | 9 | - | 9 | - | 9 |
| ISSUANCE OF COMMON STOCK, NET | 193 | 2 | 2,426 | - | 2,428 | - | 2,428 |
| STOCK-BASED COMPENSATION | 579 | 7 | 4,040 | - | 4,047 | - | 4,047 |
| STOCK-BASED COMPENSATION OF SUBSIDIARY | - | - | - | - | - | 165 | 165 |
| NET INCOME (LOSS) | - | - | - | 5,525 | 5,525 | (437) | 5,088 |
| BALANCE AS OF DECEMBER 31, 2023 | 40,339 | 485 | 320,892 | (157,556) | 163,821 | (928) | 162,893 |
| * | Represents an amount of less than $1. |
|---|
Attributable to Company’s Stockholders
| Additional · Total · Non- | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · paid-in · Accumulated · stockholders’ · controlling · Total | |||||||
| Shares | $ | capital | deficit | equity | interests | Equity | |
| In thousands | |||||||
| BALANCE AS OF JANUARY 1, 2022 | 38,158 | 459 | 292,514 | (126,520) | 166,453 | 157 | 166,610 |
| SHARES ISSUED FOR SERVICES | 3 | * | 22 | - | 22 | - | 22 |
| ISSUANCE OF COMMON STOCK, NET | 1,213 | 15 | 11,485 | - | 11,500 | - | 11,500 |
| EXERCISE OF WARRANTS AND OPTIONS | 39 | * | 62 | - | 62 | - | 62 |
| STOCK-BASED COMPENSATION | 151 | 2 | 11,117 | - | 11,119 | - | 11,119 |
| STOCK-BASED COMPENSATION OF SUBSIDIARY | - | - | - | - | - | 390 | 390 |
| TAX WITHHOLDINGS RELATED TO STOCK-BASED COMPENSATION SETTLEMENTS | - | - | (783) | - | (783) | - | (783) |
| NET LOSS | - | - | - | (36,561) | (36,561) | (1,203) | (37,764) |
| BALANCE AS OF DECEMBER 31, 2022 | 39,564 | 476 | 314,417 | (163,081) | 151,812 | (656) | 151,156 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.